The Baudette, Minn.-based company’s generic tablets are intended to treat metastatic prostate cancer when used in combination with surgical castration.
The nilutamide tablets will hit the market immediately, marking ANI’s eighth new product launch since the start of the second quarter of 2016.
The generic drug will compete against Bridgewater, N.J.-based Sonofi’s brand name version called Nilandron, which produced $23 million in sales last year.
More articles on the drug market:
FDA approves Crestor’s generic rivals, much to Astrazeneca’s dismay
India’s growing role in the US generic drug market: 5 things to know
Patients expect discounts for soaring drug costs: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.